Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine

scientific article

Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0145-2126(03)00185-1
P8608Fatcat IDrelease_rui4xmzikncu5gvsn3du5tnmsa
P698PubMed publication ID14654076

P50authorAyalew TefferiQ66370740
P2093author name stringHoffbrand AV
Butterfield JH
Pardanani A
P2860cites workTreatment of cutaneous mastocytosisQ28192647
Mastocytosis: mediator-related signs and symptomsQ33147535
Response of severe systemic mastocytosis to interferon alphaQ33502416
Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapyQ34263013
Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytesQ34529077
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteriaQ35101794
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit productQ38315689
Significance of systemic mast cell disease with associated hematologic disordersQ39715028
2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignanciesQ40622052
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutationsQ40748765
Treatment of systemic mast-cell disease with cladribineQ43527780
Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patientsQ44242600
Response to interferon alfa-2b in a patient with systemic mastocytosisQ67531413
Long-term follow-up of indolent mastocytosis in adultsQ70917154
Treatment of three patients with systemic mastocytosis with interferon alpha-2bQ71709213
Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosineQ72679379
2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasiaQ73892991
Adult-onset urticaria pigmentosa and systemic mast cell diseaseQ93655431
P433issue2
P921main subjectmast cellQ191989
P304page(s)127-131
P577publication date2004-02-01
P1433published inLeukemia ResearchQ15716445
P1476titleTreatment of systemic mast cell disease with 2-chlorodeoxyadenosine
P478volume28

Reverse relations

cites work (P2860)
Q333669212-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome
Q82207899A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis
Q46227941Advanced mast cell disease: an Italian Hematological Multicenter experience
Q43225680Cladribine inhibits a diltiazem-induced increase in red blood cell purine nucleotide concentrations in a zebrafish model.
Q92276375Clinical potential of midostaurin in advanced systemic mastocytosis
Q38661465Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial
Q36730397International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.
Q55286285KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia.
Q37195681KIT and mastocytosis
Q38045311Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive
Q36839953Mastocytosis: advances in diagnosis and treatment.
Q35994902Mastocytosis: pathology, genetics, and current options for therapy
Q38582624Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease
Q47727992Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis
Q36583570Novel approaches in the treatment of systemic mastocytosis
Q26748784Pharmacological treatment options for mast cell activation disease
Q59810100Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
Q52731268Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience.
Q46575598Systemic mastocytosis
Q83304407Systemic mastocytosis
Q45058347Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management
Q37992835Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management
Q38110527Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management
Q38358282Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management
Q39267824Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management
Q36182749Systemic mastocytosis: bone marrow pathology, classification, and current therapies
Q46727970Thalidomide in advanced mastocytosis
Q33406035Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study
Q42234623The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm